Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
11.79 USD
−352.09 M USD
26.82 M USD
55.13 M
About Agios Pharmaceuticals, Inc.
Sector
CEO
Brian M. Goff
Headquarters
Cambridge
Website
Founded
2007
FIGI
BBG000QY4ZD0
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AGIO is 58.66 USD — it has decreased by −0.74% in the past 24 hours. Watch Agios Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Agios Pharmaceuticals, Inc. stocks are traded under the ticker AGIO.
AGIO stock has risen by 8.05% compared to the previous week, the month change is a 28.67% rise, over the last year Agios Pharmaceuticals, Inc. has showed a 172.46% increase.
We've gathered analysts' opinions on Agios Pharmaceuticals, Inc. future price: according to them, AGIO price has a max estimate of 57.00 USD and a min estimate of 46.00 USD. Watch AGIO chart and read a more detailed Agios Pharmaceuticals, Inc. stock forecast: see what analysts think of Agios Pharmaceuticals, Inc. and suggest that you do with its stocks.
AGIO reached its all-time high on Jan 15, 2015 with the price of 138.85 USD, and its all-time low was 15.77 USD and was reached on Nov 18, 2013. View more price dynamics on AGIO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AGIO stock is 2.82% volatile and has beta coefficient of 2.07. Track Agios Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Agios Pharmaceuticals, Inc. there?
Today Agios Pharmaceuticals, Inc. has the market capitalization of 3.37 B, it has increased by 3.27% over the last week.
Yes, you can track Agios Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Agios Pharmaceuticals, Inc. is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
AGIO earnings for the last quarter are 16.22 USD per share, whereas the estimation was 15.22 USD resulting in a 6.60% surprise. The estimated earnings for the next quarter are −1.68 USD per share. See more details about Agios Pharmaceuticals, Inc. earnings.
Agios Pharmaceuticals, Inc. revenue for the last quarter amounts to 9.00 M USD, despite the estimated figure of 9.44 M USD. In the next quarter, revenue is expected to reach 9.31 M USD.
AGIO net income for the last quarter is 947.91 M USD, while the quarter before that showed −96.12 M USD of net income which accounts for 1.09 K% change. Track more Agios Pharmaceuticals, Inc. financial stats to get the full picture.
No, AGIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 383.00 employees. See our rating of the largest employees — is Agios Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Agios Pharmaceuticals, Inc. EBITDA is −401.29 M USD, and current EBITDA margin is −1.43 K%. See more stats in Agios Pharmaceuticals, Inc. financial statements.
Like other stocks, AGIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Agios Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Agios Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Agios Pharmaceuticals, Inc. stock shows the strong buy signal. See more of Agios Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.